A Prospective Crossover Clinical Trial of Esaxerenone and Eplerenone in Patients with Chronic Heart Failure Complicated by Hypertension
Open Access
Abstract
Esaxerenone, which blocks aldosterone binding, is approved to treat hypertension but not heart failure. We aimed to understand esaxerenone’s efficacy in treating chronic heart failure. This crossover study compared esaxerenone with eplerenone, an approved treatment for heart failure, in 66 patients with chronic heart failure complicated by hypertension (12 months for each drug). The primary endpoint was brain natriuretic peptide. The secondary endpoints included blood pressure; hormones and enzymes that regulate electrolytes and stress response; and biomarkers of kidney function. Change in brain natriuretic peptide concentration was significantly lower for esaxerenone compared with eplerenone at 3, 6, and 12 months. Blood pressure (all time points), plasma aldosterone concentration (3 and 6 months), and urinary albumin-to-creatinine ratio (3 and 6 months) were significantly lower for esaxerenone compared with eplerenone. The results suggest that esaxerenone more strongly blocks aldosterone binding than does eplerenone. This effect, together with its strong antihypertensive effect and reduced urinary albumin-to-creatinine ratio, suggests that esaxerenone improves kidney function. The results of this small-scale, single-center study need to be expanded to a larger-scale investigation, but esaxerenone shows promise as a treatment for chronic heart failure with hypertension.Keywords
This publication has 39 references indexed in Scilit:
- Efficacy and Safety of Angiotensin Receptor–Neprilysin Inhibition in Heart Failure Patients with End-Stage Kidney Disease on Maintenance Dialysis: A Systematic Review and Meta-AnalysisEuropean Journal of Heart Failure, 2024
- Antihypertensive Effect of Long-Term Monotherapy with Esaxerenone in Patients with Essential Hypertension: Relationship Between Baseline Urinary Sodium Excretion and Its Antihypertensive EffectAdvances in Therapy, 2022
- Efficacy and safety of esaxerenone (CS-3150) in Japanese patients with type 2 diabetes and macroalbuminuria: a multicenter, single-arm, open-label phase III studyClinical and Experimental Nephrology, 2021
- Independent regulation of renin–angiotensin–aldosterone system in the kidneyClinical and Experimental Nephrology, 2018
- Characterization of Heart Failure Patients with Mid-Range Left Ventricular Ejection Fraction—a Report from the CHART-2 StudyEuropean Journal of Heart Failure, 2017
- CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive ratsEuropean Journal of Pharmacology, 2015
- Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonistEuropean Journal of Pharmacology, 2015
- Review of aldosterone- and angiotensin II-induced target organ damage and preventionCardiovascular Research, 2004
- Low-dose continuous infusion of human atrial natriuretic peptide during and after cardiac surgeryThe Annals of Thoracic Surgery, 2000
- Effectiveness of Spironolactone Added to an Angiotensin-Converting Enzyme Inhibitor and a Loop Diuretic for Severe Chronic Congestive Heart Failure (The Randomized Aldactone Evaluation Study [RALES])**See Appendix for full list of RALES investigators.The American Journal of Cardiology, 1996